November 16, 2018 07:25 AM EST

AbbVie touts promising PhIII data for Orilissa as execs line up their second pitch and rivals lay in wait

Researchers for AbbVie have detailed their data from a pair of Phase III uterine fibroid studies for Orilissa which they expect will push them to …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ab­b­Vie touts promis­ing PhI­II da­ta for Orilis­sa as ex­ecs line up their sec­ond pitch and ri­vals lay in wait